We found TIL and CAF markers to be variably expressed across this cohort of PDAC patients, and we found CD200 to be heterogeneously expressed in both the tumor and stromal compartments of the cohort, with 36% of patients demonstrating positive tumor expression of the protein and 73% of patients showing positive stromal expression. This evidence concerns the gene CD200 and neoplasm.